We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Ground-breaking new cancer treatments have moved a step closer with the signing of a major agreement between the government and BioNTech SE.
First published during the 2022 to 2024 Sunak Conservative government
Around three-quarters of the £50 million funding pledged towards cutting edge research into motor neurone disease (MND) has now been handed out to projects across the UK, the government has announced today (Wednesday 21 June…
The legislative changes will help to make the UK one of the best countries in the world to conduct clinical research for patients and researchers.
The UK Government has named two leaders in dementia research to spearhead the ambitious national Mission to tackle dementia.
Patients will benefit from cutting-edge new treatments as the government introduces a Vaccine Taskforce style approach to tackling health challenges.
Government’s Vaccine Taskforce has granted £10.65 million in additional funding to support the launch of Darlington RNA vaccine innovation centre.
First published during the 2022 Truss Conservative government
Following its success during the COVID-19 pandemic, the functions of the Vaccine Taskforce will be embedded as a permanent part of government structures.
First published during the 2019 to 2022 Johnson Conservative government
People are encouraged to contribute their views on far-reaching proposed revisions to the clinical trial legislation in the UK
This new combination treatment is for people with mild to moderate COVID-19 who are at high risk of developing severe COVID-19
This new guidance follows consultation with stakeholders from the pharmaceutical industry, academic research, trade associations, patient organisations/charities, healthcare providers and regulatory organisations.
Portsmouth’s Queen Alexandra Hospital is trialing a test that could reduce burden on the NHS by predicting sepsis in patients.
Speech by Minister for Innovation Lord Bethell at the National Institute for Health Research (NIHR) Clinical Research Network National Industry Event.
MHRA Chief Executive Dr June Raine explains the process behind the Agency's approval of the Pfizer/BioNTech vaccine
We are reviewing the risks and benefits of the acne medicine, isotretinoin. In particular whether some of the possible psychiatric and sexual side effects continue after treatment has been stopped.
The MHRA has approved the recruitment of further participants for a clinical trial by the University of Oxford
The Medicines and Healthcare products Regulatory Agency (MHRA) has instructed UK clinical trialists using hydroxychloroquine to treat or prevent coronavirus (COVID-19) to suspend recruitment of further participants.
The UK organised the Global Vaccine Summit 2020 on 4 June, helping secure US$7.4 billion (approximately £6 billion) in funding to support global vaccine supply and immunisation.
MHRA has today given the first positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for use of Gilead’s remdesivir.
This will accelerate the development of new drugs for patients hospitalised with COVID-19, reducing the time taken to set up clinical studies for new therapies from months to weeks.
We are prioritising and giving tailored scientific advice for potential treatments for coronavirus (COVID-19).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).